• 107328  Infos

Bacteroides fragilis

    Bacteroides fragilis is an obligate anaerobe of the gut. It is involved in 90% of anaerobic peritoneal infections. In general, B. fragilis is susceptible to metronidazole, carbapenems, beta-lactam/beta-lactamase inhibitor combinations (e.g., Unasyn, Zosyn), and certain antimicrobials of the cephamycin class, including cefoxitin. The bacteria have inherent high-level resistance to penicillin. Clindamycin is no longer recommended as the first-line agent for B. fragilis due to emerging high-level resistance (>30% in some reports).
    Bacteriophages infecting B. fragilis are commonly used as tracers of human faecal material; see work undertaken by the University of Barcelona and EPHRU (Environment and Public Health Research Unit) at the University of Brightonhttp://sesis.eng.bton.ac.uk/environment/research/earth_systems/ephru/index.htm.
    Polysaccharide A (PSA) from this bacteria is reported to be involved in the protection of experimental colitis induced by Helicobacter hepaticus. A microbial symbiosis factor prevents intestinal inflammatory disease